Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies
| Autor: | Akihiro Iida, Kyoko Kurihara, Yusuke Takahara, Tsugumine Shu, Chikaya Moriya, Satoshi Horiba, Tetsuro Matano, Takeo Kamada, Makoto Inoue, Mamoru Hasegawa, Hiroto Hara |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
viruses
Genetic Vectors Gene Products gag CD8-Positive T-Lymphocytes Injections Intramuscular Sendai virus Viral vector Antigen Medicine Animals Vector (molecular biology) Administration Intranasal Drug Carriers General Veterinary General Immunology and Microbiology biology business.industry Immunogenicity Public Health Environmental and Occupational Health SAIDS Vaccines virus diseases respiratory system Vector vaccine biology.organism_classification Virology Vaccination Infectious Diseases Immunization Immunology Molecular Medicine Macaca Simian Immunodeficiency Virus business |
| Zdroj: | Vaccine. 29(47) |
| ISSN: | 1873-2518 |
| Popis: | Viral vectors are promising vaccine tools for eliciting potent cellular immune responses. Pre-existing anti-vector antibodies, however, can be an obstacle to their clinical use in humans. We previously developed a Sendai virus (SeV) vector vaccine and showed the potential of this vector for efficient CD8 + T-cell induction in macaques. Here, we investigated the immunogenicity of SeV vector vaccination in the presence of anti-SeV antibodies. We compared antigen-specific CD8 + T-cell responses after intranasal or intramuscular immunization with a lower dose (one-tenth of that in our previous studies) of SeV vector expressing simian immunodeficiency virus Gag antigen (SeV-Gag) between naive and pre-SeV-infected cynomolgus macaques. Intranasal SeV-Gag immunization efficiently elicited Gag-specific CD8 + T-cell responses not only in naive but also in pre-SeV-infected animals. In contrast, intramuscular SeV-Gag immunization induced Gag-specific CD8 + T-cell responses efficiently in naive but not in pre-SeV-infected animals. These results indicate that both intranasal and intramuscular SeV administrations are equivalently immunogenic in the absence of anti-SeV antibodies, whereas intranasal SeV vaccination is more immunogenic than intramuscular in the presence of anti-SeV antibodies. It is inferred from a recent report investigating the prevalence of anti-SeV antibodies in humans that SeV-specific neutralizing titers in more than 70% of people are no more than those at the SeV-Gag vaccination in pre-SeV-infected macaques in the present study. Taken together, this study implies the potential of intranasal SeV vector vaccination to induce CD8 + T-cell responses even in humans, suggesting a rationale for proceeding to a vaccine clinical trial using this vector. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect